PReS-FINAL-2147: Immunological consequences of biologicals in juvenile idiopathic arthritis
نویسندگان
چکیده
Introduction Since biologicals antagonize cytokines or receptors involved in the immune system, one could fear that their (long-term) use might affect the quality of the immune system, leading to a defective defense mechanism against infections and tumors, an insufficient response to vaccinations, or a flawed immunoregulation resulting in autoimmunity or autoinflammation. Finally, a biological agent itself can be handled as an antigen by the immune system, producing antibodies against the biological.
منابع مشابه
PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register
PReS-FINAL-2146: Trends in prescription of biologics and outcomes of juvenile idiopathic arthritis; results of the Dutch national arthritis and biologicals in children register MH Otten, J Anink, FH Prince, M Twilt, SJ Vastert, R Ten Cate, EP Hoppenreijs, W Armbrust, SL Gorter, PA Van Pelt, S Kamphuis, KM Dolman, JF Swart, JM Van den Berg, Y Koopman-Keemink, MA Van Rossum, NM Wulffraat, LA Van ...
متن کاملWhat are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?
This review summarizes the immunological consequences of biological therapies used in juvenile idiopathic arthritis (JIA). For every frequently used biological agent the characteristics are clearly specified (molecular target, isotype, registered indication for JIA, route of administration, half-life, contraindication, very common side effects, expected time of response and average cost in the ...
متن کاملPReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial
PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial C Malattia, N Ruperto, E Palmisani, S Pederzoli, A Pistorio, HI Brunner, R Cuttica, I Calvo, SM Garay, D Eleftheriou, C Wouters, J Wang, C Devlin, D Lovell, A Martini, F De Benedetti, A Ravelli, PRCSG an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 11 شماره
صفحات -
تاریخ انتشار 2013